On 18 April 2024, the US Food and Drug Administration (FDA) approved Roche’s Alecensa (alectinib), an oral anaplastic ...

Much of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a decision expected in a matter ...

A djuvant radiotherapy (RT) after radical prostatectomy did not improve outcomes in prostate cancer as compared with salvage ...

Agricultural Activator Adjuvant Market set to hit worth US$ 6.6 billion at CAGR 4.9% during forecast period 2024 to 2034 ...

Welcome to the Moderna's first-quarter 2024 conference call. [Operator instructions] Please be advised, today's conference is ...

Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear ...

The global agricultural adjuvant market is forecast to expand at 6% CAGR over the forecast period, as per FMI’s analysis. The ...

Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA ...

The FDA has approved Alecensa (alectinib) as adjuvant treatment for adults with ALK-positive non-small cell lung cancer.

The US Food and Drug Administration (FDA) has approved alectinib (Alecensa, Genentech) in the adjuvant setting following ...

Alectinib approved by US FDA for auxiliary treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small ...